Related Experiment Video
Updated: Jul 9, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
22.1K
[In vivo CAR-Ts, a significant breakthrough]
1Biologiste, généticien, Président d'Aprogène (association pour la promotion de la génomique), Marseille, France.
Medecine Sciences : M/S
|March 20, 2026
Summary
A new in vivo chimeric antigen receptor T-cell (CAR-T) therapy transforms T cells within the body, offering a simpler, faster, and more affordable alternative to complex ex vivo CAR-T treatments for B cell malignancies and autoimmune diseases.
Area of Science:
- Immunotherapy
- Cellular Therapy
- Oncoimmunology
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy, established in 2017, has shown significant success in treating B cell malignancies.
- Current ex vivo CAR-T approaches are complex and costly, limiting widespread application.
Purpose of the Study:
- To introduce and evaluate a novel in vivo method for CAR-T cell generation.
- To explore the potential of this new approach for treating B cell malignancies and autoimmune diseases.
Main Methods:
- In situ (in vivo) transformation of T lymphocytes into CAR-T cells.
- Evaluation of simplicity, speed, and affordability compared to ex vivo methods.
Main Results:
- The in vivo method offers a promising alternative to traditional ex vivo CAR-T therapy.
- This approach demonstrates potential applicability to autoimmune diseases.
Conclusions:
- In vivo CAR-T generation presents a simplified, faster, and more affordable therapeutic strategy.
- This innovative method is attracting significant interest in both academic and corporate research environments.
Related Concept Videos
01:17Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
01:20Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...